Man Group plc Invests $7.33 Million in BioCryst Pharmaceuticals, Inc. $BCRX

Man Group plc acquired a new stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 732,867 shares of the biotechnology company’s stock, valued at approximately $7,329,000.

Several other large investors have also recently made changes to their positions in BCRX. Jupiter Topco LLC bought a new position in shares of BioCryst Pharmaceuticals during the 2nd quarter valued at approximately $95,268,000. Elmind Capital LP bought a new stake in shares of BioCryst Pharmaceuticals in the 2nd quarter worth approximately $5,200,000. ADAR1 Capital Management LLC purchased a new position in BioCryst Pharmaceuticals in the second quarter valued at approximately $1,330,000. Hsbc Holdings PLC bought a new position in BioCryst Pharmaceuticals during the second quarter valued at $1,079,000. Finally, PDT Partners LLC bought a new position in BioCryst Pharmaceuticals during the second quarter valued at $245,000. 85.88% of the stock is owned by hedge funds and other institutional investors.

BioCryst Pharmaceuticals Trading Down 0.5%

Shares of BCRX opened at $9.82 on Friday. BioCryst Pharmaceuticals, Inc. has a 12-month low of $6.00 and a 12-month high of $11.22. The company has a market cap of $2.51 billion, a PE ratio of -6.55 and a beta of 0.55. The stock has a 50-day moving average price of $9.71 and a 200-day moving average price of $9.05.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $0.30 earnings per share for the quarter, beating the consensus estimate of $0.15 by $0.15. BioCryst Pharmaceuticals had a negative net margin of 40.90% and a negative return on equity of 86.89%. The firm had revenue of $218.25 million for the quarter, compared to analysts’ expectations of $183.28 million. During the same quarter last year, the company posted $0.15 EPS. The business’s quarterly revenue was up 33.6% on a year-over-year basis. As a group, analysts predict that BioCryst Pharmaceuticals, Inc. will post -2.25 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on BCRX. Royal Bank Of Canada decreased their price objective on BioCryst Pharmaceuticals from $14.00 to $13.00 and set an “outperform” rating for the company in a report on Thursday, August 6th. Citizens Jmp upped their price objective on shares of BioCryst Pharmaceuticals from $25.00 to $28.00 and gave the company a “market outperform” rating in a report on Thursday, May 7th. Wall Street Zen lowered shares of BioCryst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday. JPMorgan Chase & Co. began coverage on shares of BioCryst Pharmaceuticals in a research report on Monday, July 13th. They issued a “neutral” rating and a $12.00 price target on the stock. Finally, HC Wainwright restated a “buy” rating and set a $32.00 price target on shares of BioCryst Pharmaceuticals in a research note on Tuesday, June 30th. Eight analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $20.60.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.